Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

Editor

Personal info

View

About

Terms

Javascript disabled

Please enable Javascript support in your browser to use this application.

Instructions on how to enable JavaScript on different browsers can be found here: http://www.google.com/support/bin/answer.py?answer=23852.

[edit this page]

Gene Review:

GHRL - ghrelin/obestatin prepropeptide

Canis lupus familiaris

Synonyms: MTLRP, MTLRP-AP

Jacks, T. et al., Rigamonti, A.E. et al., Shen, Y.T. et al., Roumi, M. et al.

Shen, Lynch, Hargreaves, Gould,

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of GHRL

A growth hormone secretagogue prevents ischemic-induced mortality independently of the growth hormone pathway in dogs with chronic dilated cardiomyopathy [1].

High impact information on GHRL

Radioimmunoassay for hexarelin, a peptidic growth hormone secretagogue, and its pharmacokinetic studies [2].
Based on peak responses and total GH release, L-692,585 was 10- to 20-fold and 2- to 2.5-fold more potent than L-692,429 and the growth hormone releasing peptide, GHRP-6, respectively [3].
Effects of acute and repeated intravenous administration of L-692,585, a novel non-peptidyl growth hormone secretagogue, on plasma growth hormone, IGF-1, ACTH, cortisol, prolactin, insulin, and thyroxine levels in beagles [3].
Orexigenic effects of a growth hormone secretagogue and nitric oxide in aged rats and dogs: correlation with the hypothalamic expression of some neuropeptidergic/receptorial effectors mediating food intake [4].

References

A growth hormone secretagogue prevents ischemic-induced mortality independently of the growth hormone pathway in dogs with chronic dilated cardiomyopathy. Shen, Y.T., Lynch, J.J., Hargreaves, R.J., Gould, R.J. J. Pharmacol. Exp. Ther. (2003) [Pubmed]
Radioimmunoassay for hexarelin, a peptidic growth hormone secretagogue, and its pharmacokinetic studies. Roumi, M., Lenaerts, V., Boutignon, F., Wuthrich, P., Deghenghi, R., Bellemare, M., Adam, A., Ong, H. Peptides (1995) [Pubmed]
Effects of acute and repeated intravenous administration of L-692,585, a novel non-peptidyl growth hormone secretagogue, on plasma growth hormone, IGF-1, ACTH, cortisol, prolactin, insulin, and thyroxine levels in beagles. Jacks, T., Hickey, G., Judith, F., Taylor, J., Chen, H., Krupa, D., Feeney, W., Schoen, W., Ok, D., Fisher, M. J. Endocrinol. (1994) [Pubmed]
Orexigenic effects of a growth hormone secretagogue and nitric oxide in aged rats and dogs: correlation with the hypothalamic expression of some neuropeptidergic/receptorial effectors mediating food intake. Rigamonti, A.E., Bonomo, S.M., Scanniffio, D., Cella, S.G., Müller, E.E. J. Gerontol. A Biol. Sci. Med. Sci. (2006) [Pubmed]

Contributions to this collaborative article are from individual authors of WikiGenes or mined by the WikiGenes Data Mining Engine from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.About WikiGenes Open Access Licence Privacy Policy Terms of Use apsburg